COMMUNIQUÉS West-GlobeNewswire
-
A Race Against Blindness Announces Spring 2026 Luxury Vehicle Fundraiser in Partnership with Foundation Fighting Blindness to Advance Pediatric Inherited Retinal Disease Research
16/03/2026 -
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
16/03/2026 -
Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility
16/03/2026 -
Extendicare Announces March 2026 Dividend of C$0.0441 per Share
16/03/2026 -
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
16/03/2026 -
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
16/03/2026 -
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
16/03/2026 -
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
16/03/2026 -
TOMI Environmental Solutions Expands Footprint Across Canada
16/03/2026 -
Flyte Launches Florida Hops to Service Accelerating Demand
16/03/2026 -
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
16/03/2026 -
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
16/03/2026 -
Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation
16/03/2026 -
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
16/03/2026 -
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
16/03/2026 -
Nordletics Makes Home Fitness Simple and Personalized
16/03/2026 -
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
16/03/2026 -
Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease
16/03/2026 -
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
16/03/2026
Pages